BL-B01D1 combination therapy for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug combination (BL-B01D1) for men with advanced prostate cancer that has stopped responding to hormone therapy. The study aims to see if this treatment can slow cancer growth and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with metastatic castration-resistant prostate cancer (advanced prostate cancer that no longer responds to hormone-lowering treatments)
- Your cancer cannot be surgically removed and has spread to other parts of your body
- You are at least 18 years old and expected to live at least 3 months
- You are in good enough health to handle treatment (ECOG score 0 or 1, meaning you can do light activities or are mostly confined to bed/chair less than 50% of the day)
- You have a tissue sample (old or fresh) from your cancer available for testing
- Your heart, liver, and kidney function meet safe levels for the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (GZ17-6.02) for men with advanced prostate cancer that has stopped responding to standard hormone therapies. The goal is to see if the drug can help slow down the cancer.
This study tests a new drug called BL-B01D1 against standard treatment options for patients with advanced biliary tract cancer (cancer of the bile ducts) that has stopped responding to platinum chemotherapy and immunotherapy. The drug is designed to target and destroy cancer cells more effectively.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This trial tests a new targeted drug called BL-B01D1 against standard chemotherapy in patients with advanced breast cancer that is hormone-receptor-positive (HR+) and HER2-negative, and has stopped responding to hormone treatments. The goal is to see if the new drug works better or has fewer side effects.
This trial studies how well the combination of olaparib and abiraterone works for men with advanced prostate cancer that has stopped responding to hormone therapy. If you are already taking or planning to take this combination, researchers want to learn more about its long-term benefits and safety.
This trial combines three treatments—a targeted radioactive therapy (177Lu-PSMA), a PARP inhibitor (olaparib), and an immunotherapy (pembrolizumab)—to see if they work better together against advanced prostate cancer that has stopped responding to hormone therapy. You may join if your cancer shows strong PSMA on scans and you have already tried certain hormone blockers but your cancer continued to grow.
Hear when a new Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.